Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$42.96 USD
-0.79 (-1.81%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $42.94 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KYMR 42.96 -0.79(-1.81%)
Will KYMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Other News for KYMR
Kymera Therapeutics (KYMR) Gains Support as Data Release Approaches
Kymera Therapeutics transferred with Buy rating at B. Riley
Goldman Sachs Initiates Coverage on Kymera Therapeutics (KYMR) as Early-Stage Biotech | KYMR ...
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
Gilead sees Q2 EPS hit from IPR&D expenses